Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 24 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-1.60 Insider Own5.84% Shs Outstand41.08M Perf Week-3.99%
Market Cap37.39M Forward P/E- EPS next Y-1.10 Insider Trans0.00% Shs Float38.69M Perf Month17.51%
Income-64.55M PEG- EPS next Q-0.44 Inst Own51.40% Short Float0.04% Perf Quarter-33.09%
Sales0.00M P/S- EPS this Y43.68% Inst Trans0.48% Short Ratio0.04 Perf Half Y14.04%
Book/sh3.17 P/B0.29 EPS next Y-12.76% ROA-36.53% Short Interest0.01M Perf Year-13.74%
Cash/sh2.73 P/C0.33 EPS next 5Y5.20% ROE-40.91% 52W Range0.74 - 1.76 Perf YTD2.36%
Dividend Est.- P/FCF- EPS past 5Y- ROI-49.30% 52W High-48.30% Beta1.33
Dividend TTM- Quick Ratio9.63 Sales past 5Y0.00% Gross Margin- 52W Low22.97% ATR (14)0.06
Dividend Ex-Date- Current Ratio9.63 EPS Y/Y TTM3.33% Oper. Margin0.00% RSI (14)51.85 Volatility5.67% 6.17%
Employees215 Debt/Eq0.03 Sales Y/Y TTM- Profit Margin- Recom2.67 Target Price2.83
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q31.51% Payout- Rel Volume0.22 Prev Close0.90
Sales Surprise- EPS Surprise35.25% Sales Q/Q- EarningsMay 08 BMO Avg Volume376.54K Price0.91
SMA205.01% SMA50-3.81% SMA200-2.97% Trades Volume82,027 Change1.53%
Date Action Analyst Rating Change Price Target Change
Apr-05-24Downgrade Piper Sandler Overweight → Neutral $8 → $2
Apr-26-21Initiated Piper Sandler Overweight $25
Apr-26-21Initiated Oppenheimer Outperform $23
Apr-26-21Initiated JP Morgan Underweight $11
Apr-26-21Initiated Chardan Capital Markets Buy $27
Apr-26-21Initiated BofA Securities Buy $20
May-22-24 07:00AM
May-17-24 05:00PM
May-08-24 01:53PM
Apr-04-24 11:53AM
06:45AM Loading…
Feb-05-24 07:00AM
Dec-18-23 07:00AM
Nov-13-23 04:30PM
Oct-24-23 12:30PM
Sep-22-23 04:30PM
Sep-13-23 12:05PM
Sep-06-23 09:40AM
11:50AM Loading…
Aug-10-23 11:50AM
Aug-04-23 07:00AM
Jun-12-23 08:00AM
May-21-23 10:03AM
May-10-23 07:15AM
Apr-25-23 06:00PM
Apr-22-23 09:45AM
Apr-17-23 08:00AM
Mar-07-23 07:00AM
Feb-02-23 09:40AM
Jan-17-23 09:40AM
Dec-20-22 08:30AM
Dec-06-22 06:00AM
06:05PM Loading…
Nov-30-22 06:05PM
Nov-22-22 08:00AM
Nov-13-22 07:48AM
Nov-08-22 07:00AM
Nov-01-22 12:00PM
Oct-06-22 08:30AM
Sep-07-22 01:15PM
Aug-31-22 12:53PM
Aug-26-22 01:34PM
Aug-25-22 11:53AM
Aug-24-22 01:33PM
Aug-23-22 01:53PM
Aug-19-22 12:32PM
Aug-16-22 10:09AM
Aug-09-22 07:00AM
Aug-01-22 06:00AM
Jul-21-22 08:00AM
Jun-30-22 08:00AM
Jun-21-22 08:30AM
Jun-06-22 08:40AM
May-10-22 07:00AM
May-09-22 07:00AM
May-04-22 08:00AM
May-03-22 08:00AM
Apr-14-22 11:27AM
Apr-12-22 07:30AM
Apr-05-22 08:00AM
Apr-04-22 08:00AM
Mar-08-22 08:00AM
Mar-01-22 09:00AM
Feb-07-22 07:30AM
Jan-13-22 07:30AM
Dec-28-21 04:09AM
Dec-21-21 08:00AM
Dec-20-21 08:00AM
Dec-09-21 07:00AM
Nov-12-21 07:00AM
Nov-10-21 08:15AM
Nov-09-21 08:00AM
Oct-22-21 07:30AM
Oct-12-21 08:00AM
Oct-01-21 08:00AM
Sep-29-21 06:15AM
Sep-02-21 08:30AM
Aug-25-21 08:00AM
Aug-10-21 07:00AM
Jul-26-21 03:00PM
Jul-01-21 08:00AM
Jun-04-21 09:00AM
May-11-21 07:00AM
May-06-21 08:00AM
May-05-21 08:30AM
May-03-21 08:00AM
Apr-10-21 08:30AM
Apr-06-21 04:01PM
Mar-31-21 02:01PM
Mar-30-21 07:00PM
Achilles Therapeutics Plc is a biopharmaceutical company engaged in developing transformative precision T-cell therapies to treat multiple types of solid tumors. It focuses on researching, developing and commercializing potentially novel cancer immunotherapies targeting clonal neoantigens. The company was founded by Karl Peggs, Sergio Quezada, Mark Lowdell and Charles Swanton in November 2020 and is headquartered in London, the United Kingdom.